



XIV Congreso Nacional de Biotecnología y Bioingeniería



EXPRESSION OF AN ANTIVIRAL RECOMBINANT PROTEIN OBTAINED FROM *LONOMIA OBLIQUA* HEMOLYMPH IN A BACULOVIRUS/CELLS



Ana C.V. Carmo,^{1,2,4} Dalton .N.S. Giovanni,² Rita C. Stocco², Ana B.G. Veiga⁵, Roberto H.P. Moraes¹, Claudio.A.T. Suazo⁴ Rita, M.Z. Mendonça³, **Ronaldo Z. Mendonça**¹: *1 Parasitology and Entomology laboratory, Instituto Butantan, São Paulo/SP 2 Genetic laboratory, Instituto Butantan, 3 Virology laboratory, Instituto Butantan, 4 Technology and cell culture laboratory, São Carlos/SP 5. Universidade Federal de Ciências da Saúde de Porto Alegre, Key words: antiviral, recombinant protein, Lonomia obliqua*

Introduction. The control of viruses, especially those induced by influenza virus is of great interest to the public health area. Several studies have been conducted that show the presence of pharmacologically active substances in the hemolymph. Recently we have demonstrated the existence of a potent antiviral in hemolymph of *Lonomia obliqua* caterpillar. This purified protein reduced virus production by more than 157 fold (from $3.3 \pm 1.25 \times 10^7$ to $2.1 \pm 1.5 \times 10^5$) to measles virus, 61 fold to polio virus ($2.8 \pm 1.08 \times 10^9$ to $4.58 \pm 1.42 \times 10^7$) and 64 fold to H₁N₁ influenza virus (Antiviral Research 84, 84-90, 2009). Thus, this study aim to build recombinants bacmids containing sequences encoding this antiviral protein in baculovirus/SF-9 cell system.

Methodology. To synthesize cDNA, RNA of *L. obliqua* was extracted with Trizol reagent and used in polymerase chain reactions using reverse transcriptase polymerase (RT-PCR) with primers specific for the antiviral protein. Restriction sites were inserted in the cDNA for connection to the donor plasmid pFastBac1TM (Invitrogen). The recombinant plasmid was selected in *Escherichia coli* DH5 α and subsequently used in the transformation of DH10Bac *E. coli*, to obtain the recombinant bacmid. This bacmid was used for expression of this protein in baculovirus/insect cells system. Samples of the supernatant of infected cultures were collected daily, concentrated and subjected to SDS-PAGE chromatography. A protein band around 20 kDa was observed. Studies on the activity of the recombinant protein were performed with the supernatant of infected culture applied in cultures infected with influenza virus. These studies showed that the protein was capable of reduced virus production.

Results. The results are presented below. Figure 1 shows the agarose gels to confirm amplification of the antiviral protein sequence (1a), the release of the insert after digestion with enzymes used for cloning (1b) and the amplification of the protein sequence (1c). Figure 2 is presented the colonies containing the recombinant bacmid after transformation into *E. DH10Bac*TM *coli*. Figure 3 presents the electrophoresis gels of infected cells with bacmids (3a) and an SDS-PAGE electrophoresis of infected culture supernatant of recombinant baculovirus infected with recombinant the antiviral protein. Figure 4 shows an electron microscopy of recombinant baculovirus. Figure 5 shown the effect of antiviral recombinant protein in EMC virus replication. Control cell (a) infected cells with EMC virus (b) and the

protective effect of recombinant protein in a culture infected with the virus (c).



Conclusión:

In this study, recombinant bacmid containing the sequence encoding this antiviral protein was produced and expressed in baculovirus/SF-9 cell system. The recombinant protein obtained was able to block the replication of EMC virus replication.

Financial support: FAPESP (08/57263-5), CAPES. **Bibliography.** Antiviral Research 84, 84-90, (2009).



XIV Congreso Nacional de Biotecnología y Bioingeniería

